Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

Transcatheter aortic valve implantation (TAVI) has been shown to generate the best clinical outcomes when performed by the percutaneous transfemoral approach. Intravascular lithotripsy (IVL) can facilitate a transfemoral process in patients with calcified iliofemoral vascular disease and borderline intraluminal diameters. The present protocol describes IVL-assisted transfemoral TAVI.

Abstract

During the last decade, transcatheter aortic valve implantation (TAVI) has evolved as a well-established therapy for aging patients suffering from symptomatic severe aortic valve stenosis. This is also reflected in the recently updated international guidelines on managing patients with valvular heart disease. A transfemoral (TF) TAVI approach has proven superior to alternative access strategies. With the introduction of intravascular lithotripsy (IVL), patients with calcified iliofemoral vascular disease and borderline intraluminal diameters have also become candidates for percutaneous TF-TAVI. Moreover, IVL reduces the risk of major vascular complications by modifying the superficial and deep vascular calcium, thereby changing the vessel compliance and controlling luminal expansion. In this way, IVL has shown to safely facilitate TF delivery of TAVI devices in patients with calcified peripheral artery disease. The present article aims to provide a detailed step-by-step description on how to perform IVL-assisted TF-TAVI safely and efficiently. Furthermore, a literature review on the outcomes obtained with this technology is included, along with a concise discussion on this unique TAVI approach.

Introduction

Transcatheter aortic valve implantation (TAVI) has proven to be a valuable therapy for elderly patients suffering from symptomatic severe aortic valve stenosis (AS) across all surgical risk categories1,2. The data and outcomes are most convincing for those patients in whom the TAVI procedure can be performed by transfemoral (TF) approach. TAVI by alternative access, such as transsubclavian, transaxillary, transcarotid, transcaval, and transapical access, can also be considered. However, the complication rates reported for TAVI by alternative access are higher than TF-TAVI3,

Protocol

The protocol is approved by the human research ethics committee of Copenhagen University Hospital, and the studies are conducted following the guidelines of the said ethics committee. Following local policies, all patients gave informed consent for the TAVI procedure, cardiac CT scanning, and anonymous data for research.

1. Preprocedural planning

  1. Inspect the aorta-iliofemoral vessels ranging from the aortic valve, over the aortic arch, down to the common femoral ar.......

Representative Results

IVL treatment (Figure 1) of calcified PAD was first investigated in the DISRUPT-PAD European pre-market study18. The study showed an acute increase in vessel diameter in 35 patients following peripheral IVL treatment at the cost of only minimal vessel injury. The multi-center DISRUPT-PAD II trial19 confirmed these findings in 60 patients. DISRUPT PAD III20 was designed as a real-world, prospective, multi-center study in .......

Discussion

Since the introduction of TAVI as a treatment option for patients with severe symptomatic AS, studies and registries have demonstrated that TAVI by TF approach generates better procedural success and lower complication rates3,4,23. As a result, most centers nowadays seek to perform most of their TAVI procedures by percutaneous TF approach23.

The introduction of IVL as a new too.......

Acknowledgements

The authors have none to acknowledge.

....

Materials

NameCompanyCatalog NumberComments
0.014” guidewireFloppy II Extra Support Guide Wire, Abbott, USA22299M
0.035’’ stiff guidewireAmplatz superstiff j-tip 7 cm floppy, Boston Scientific, USAM001465020
20 mL syringe
6 F or 8 F femoral sheatRadifocus Introducer II, TerumoRS*B70N10MRD and RS*B80N10MRD
6-8 F Arrow sheat 35 cm- if contralateral accessTeleflexCL07635 and CL07835
Arterial puncture needlePercutaneous entry thinwall needle, Cook MedicalSDN18-18-7.0
Contrast solutionVisipaque 350, GE Healthcare
CT angiography-based 3D reconstruction dedicated software3mensio, Pie Medical, The Netherlands
Diagnostic catheter6F IMA diagnostic catheter, Cordis534-6605
Echo probe sterile coverCIV-flex transducer cover, CIVCO610-1212
Indeflator device (20 mL)Everest 30, MedtronicAC3200
IVL Connector CableShockwave medicalIVLCC
IVL generatorShockwave medicalIVLGCC
Local anestheticXylocain 10 mg/mL, Aspen
Non-compliant balloonZ-MED II balloon 6 to 8 mm, Numed Canada inc.PDZ622
Safety wire0.018’’ Platinum Plus guidewire, Boston Scientific, USAM0014666050
Shockwave M5/M5+ catheter (7 mm-8 mm diameter)Shockwave medicalM5IVL7060 - M5PIVL7060 - M5PIVL8060
Standard J-wireangiodyn guide wire j-tip, B. Braun5050200
Sterile cover for shockwave connector cablecamera drape, Mönlycke health care
Three-way stopcock
Unfractionated heparin10 mL vials of 1000 IE/mL, Amgros I/S
Vascular closure devicePerclose Prostyle device, Abbott, USA12773-02
Vascular echo probe
Manta VCD, Essential Medical, USA2156NE, 2115NE

References

  1. Mack, M. J., et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. The New England Journal of Medicine. 380 (18), 1695-1705 (2019).
  2. Popma, J. J., et al.

Explore More Articles

Intravascular LithotripsyTranscatheter Aortic Valve ImplantationTransfemoral TAVICalcified Iliofemoral Vascular DiseasePeripheral Artery DiseaseVascular Complications

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved